Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma - Trial NCT06353022
Access comprehensive clinical trial information for NCT06353022 through Pure Global AI's free database. This Phase 2 trial is sponsored by Nantes University Hospital and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 103 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Nantes University Hospital
Timeline & Enrollment
Phase 2
Apr 20, 2024
Jun 20, 2030
Primary Outcome
Rate of sustained MRD negativity (NGS, 10^-5),Rate of conversion from positive MRD to negative MRD (NGS, 10^-5)
Summary
This is a Phase 2 study, open-label, 2-cohort, multicenter, national, interventional in
 patients with newly diagnosed multiple myeloma. The study will investigate teclistamab (Tec)
 in combination with lenalidomide (Len) (Tec-Len; Cohort A) or in combination with talquetamab
 (Tal) (Tec-Tal; Cohort B), allocated based on minimal residual disease (MRD) status (MRD [-]
 [standard-risk] vs MRD [+] [high-risk] respectively).
 
 The patient population will consist of adults men and women at least 18 years to younger than
 66 years of age, who meet eligibility criteria.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06353022
Non-Device Trial